Journal: Scientific Reports

Article Title: Unraveling shared molecular signatures and potential therapeutic targets linking psoriasis and acute myocardial infarction

doi: 10.1038/s41598-024-67350-w

Figure Lengend Snippet: Association of immune infiltration with psoriasis and AMI. ( A ) Relative abundance of distinct immune cell subsets in GSE161683 database. ( B ) Correlation between immune cell infiltration and the expression of SLPI, S100A9, IL1B, CYBB, CXCL8, S100A12, and CXCL1 in the Psoriasis cohort. ( C ) Relative abundance of distinct immune cell subsets in GSE66360 database. ( D ) Correlation between immune cell infiltration and the expression of SLPI, S100A9, IL1B, CYBB, CXCL8, S100A12, and CXCL1 in the AMI cohort.

Article Snippet: Antibody Application: Anti-CXCL8 antibody (Proteintech, 27095-1-AP, dilution ratio: 1:100); Anti-IL-1B antibody (Affinity, DF6251, dilution ratio: 1:100); Anti-S100A9 antibody (ABclonal, A22131, dilution ratio: 1:100); Anti-S100A12 antibody (ABclonal, A12499, dilution ratio: 1:100).

Techniques: Expressing

Journal: Scientific Reports

Article Title: Unraveling shared molecular signatures and potential therapeutic targets linking psoriasis and acute myocardial infarction

doi: 10.1038/s41598-024-67350-w

Figure Lengend Snippet: Three-dimensional molecular docking diagrams of simvastatin with target proteins: ( A ) CXCL8, ( B ) IL1B, ( C ) S100A9, and ( D ) S100A12.

Article Snippet: Antibody Application: Anti-CXCL8 antibody (Proteintech, 27095-1-AP, dilution ratio: 1:100); Anti-IL-1B antibody (Affinity, DF6251, dilution ratio: 1:100); Anti-S100A9 antibody (ABclonal, A22131, dilution ratio: 1:100); Anti-S100A12 antibody (ABclonal, A12499, dilution ratio: 1:100).

Techniques:

Journal: Scientific Reports

Article Title: Unraveling shared molecular signatures and potential therapeutic targets linking psoriasis and acute myocardial infarction

doi: 10.1038/s41598-024-67350-w

Figure Lengend Snippet: Expression of hub genes in serum of AMI patients and border zone of cardiac infarction in MI mice. ELISA was used to detect the expression of CXCL8 ( A ), IL-1B ( B ), S100A9 ( C ) and S100A12 ( D ) in serum of Normal and AMI patients. ( E ) The sham group and myocardial infarction 1 d, 3 d, 7 d heart tissue in mice of HE staining and CXCL8, IL-1B and S100A9 immunohistochemical staining and quantitative ( F – H ). ( I ) The mRNA expression of Il-8, Il-1b and S100a9 in cardiac tissue of MI mice on day 1, 3, 7 and sham group were detected.

Article Snippet: Antibody Application: Anti-CXCL8 antibody (Proteintech, 27095-1-AP, dilution ratio: 1:100); Anti-IL-1B antibody (Affinity, DF6251, dilution ratio: 1:100); Anti-S100A9 antibody (ABclonal, A22131, dilution ratio: 1:100); Anti-S100A12 antibody (ABclonal, A12499, dilution ratio: 1:100).

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Staining, Immunohistochemical staining

Journal: Scientific Reports

Article Title: Unraveling shared molecular signatures and potential therapeutic targets linking psoriasis and acute myocardial infarction

doi: 10.1038/s41598-024-67350-w

Figure Lengend Snippet: High expression of disease hub genes in psoriasis skin. ( A ) Immunohistochemical staining and quantitative ( B - E ) detection of the normal skin of patients with psoriasis skin disease in CXCL8, IL-1B, S100A9 and S100A12 expression.

Article Snippet: Antibody Application: Anti-CXCL8 antibody (Proteintech, 27095-1-AP, dilution ratio: 1:100); Anti-IL-1B antibody (Affinity, DF6251, dilution ratio: 1:100); Anti-S100A9 antibody (ABclonal, A22131, dilution ratio: 1:100); Anti-S100A12 antibody (ABclonal, A12499, dilution ratio: 1:100).

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Turkish Journal of Medical Sciences

Article Title: Evaluation of S100A12 protein levels in children with familial Mediterranean fever

doi: 10.3906/sag-2009-187

Figure Lengend Snippet: Patients’ and controls’ demographic and laboratory data.

Article Snippet: For the S100A12 measurement, Elabscience Human ELISA kits (Shanghai, China, 2019) were used.

Techniques:

Journal: Turkish Journal of Medical Sciences

Article Title: Evaluation of S100A12 protein levels in children with familial Mediterranean fever

doi: 10.3906/sag-2009-187

Figure Lengend Snippet: Demographic and laboratory findings of acute attack period versus attack-free period groups.

Article Snippet: For the S100A12 measurement, Elabscience Human ELISA kits (Shanghai, China, 2019) were used.

Techniques:

Journal: Turkish Journal of Medical Sciences

Article Title: Evaluation of S100A12 protein levels in children with familial Mediterranean fever

doi: 10.3906/sag-2009-187

Figure Lengend Snippet: Demographic and laboratory findings of attack-free period versus healthy controls.

Article Snippet: For the S100A12 measurement, Elabscience Human ELISA kits (Shanghai, China, 2019) were used.

Techniques:

Journal: Turkish Journal of Medical Sciences

Article Title: Evaluation of S100A12 protein levels in children with familial Mediterranean fever

doi: 10.3906/sag-2009-187

Figure Lengend Snippet: Correlation between S100A12 level and other acute-phase reactants in the attack-free period, acute attack period, and all patients.

Article Snippet: For the S100A12 measurement, Elabscience Human ELISA kits (Shanghai, China, 2019) were used.

Techniques:

Journal: Turkish Journal of Medical Sciences

Article Title: Evaluation of S100A12 protein levels in children with familial Mediterranean fever

doi: 10.3906/sag-2009-187

Figure Lengend Snippet: Receiver operating characteristic curve analysis of acute-phase reactants in Familial Mediterranean Fever patients.

Article Snippet: For the S100A12 measurement, Elabscience Human ELISA kits (Shanghai, China, 2019) were used.

Techniques:

Journal: Turkish Journal of Medical Sciences

Article Title: Evaluation of S100A12 protein levels in children with familial Mediterranean fever

doi: 10.3906/sag-2009-187

Figure Lengend Snippet: Comparison of acute-phase reactants of patients with M694V homozygous mutation versus other mutations.

Article Snippet: For the S100A12 measurement, Elabscience Human ELISA kits (Shanghai, China, 2019) were used.

Techniques: Comparison, Mutagenesis

Journal: Arthritis Research & Therapy

Article Title: IRF7 orchestrates proinflammatory macrophage polarization and joint destruction in rheumatoid arthritis

doi: 10.1186/s13075-025-03708-3

Figure Lengend Snippet: Increased frequency and proinflammatory signature of CD48 high S100A12 + macrophages in rheumatoid arthritis synovium. A UMAP visualization of synovial macrophages clustered into nine subpopulations on the basis of scRNA-seq data. B Disease-stratified analysis showing an increased proportion of CD48 high S100A12 + macrophages in the RA synovium compared with those in the UA, OA, and HC groups. C UMAP plots depicting S100A12 expression intensity across macrophage subclusters in different disease states. D Gene Ontology (GO) enrichment of biological processes in CD48 high S100A12 + marker genes, highlighting enrichment for defense response activation, cytokine production, and leukocyte migration. E Representative images of CD68 and S100A12 immunofluorescence staining in knee synovial tissues from RA and OA patients. Scale bar: 100 μm

Article Snippet: Double immunofluorescence staining was performed as follows: sections were incubated overnight at 4 °C with primary antibodies against CD68 (mouse monoclonal, 1:100 dilution; 66231-2-Ig, Proteintech, China) with S100A12 (rabbit polyclonal, 1:100 dilution; 16630-1-AP, Proteintech, China) or CD68 (1:100 dilution; 66231-2-Ig) with IRF7 (rabbit polyclonal, 1:150 dilution; 22392-1-AP, Proteintech, China).

Techniques: Expressing, Marker, Activation Assay, Migration, Immunofluorescence, Staining

Journal: Arthritis Research & Therapy

Article Title: IRF7 orchestrates proinflammatory macrophage polarization and joint destruction in rheumatoid arthritis

doi: 10.1186/s13075-025-03708-3

Figure Lengend Snippet: IRF7 is a specific transcriptional regulator of CD48 high S100A12 + macrophages. A Venn diagram showing overlapping transcription factors (TFs) identified by triplicate SCENIC analyses, with the CD48 high S100A12 + subcluster enriched for NFIL3, TGIF1, FOSL2, IRF7, and STAT1. B Heatmap of regulon activity scores (RASs) for TFs across macrophage subclusters. C Ranking of TFs in CD48 high S100A12 + macrophages by the regulon specificity score (RSS, calculated via Jensen‒Shannon divergence). D UMAP dimensionality reduction of TF activity profiles across subclusters. E – F UMAP plots highlighting spatial overlap between the CD48 high S100A12 + subcluster. ( E ) and cells with elevated IRF7 regulon activity ( F ). G Representative images of immunofluorescence staining for CD68 and IRF7 in knee synovial tissues from RA and OA patients. Scale bar: 100 μm

Article Snippet: Double immunofluorescence staining was performed as follows: sections were incubated overnight at 4 °C with primary antibodies against CD68 (mouse monoclonal, 1:100 dilution; 66231-2-Ig, Proteintech, China) with S100A12 (rabbit polyclonal, 1:100 dilution; 16630-1-AP, Proteintech, China) or CD68 (1:100 dilution; 66231-2-Ig) with IRF7 (rabbit polyclonal, 1:150 dilution; 22392-1-AP, Proteintech, China).

Techniques: Activity Assay, Immunofluorescence, Staining

Journal: Arthritis Research & Therapy

Article Title: IRF7 orchestrates proinflammatory macrophage polarization and joint destruction in rheumatoid arthritis

doi: 10.1186/s13075-025-03708-3

Figure Lengend Snippet: IRF7 directly regulates downstream inflammatory genes in M1 macrophages. A ChIP-seq peak heatmaps showing increased IRF7 binding to promoter/enhancer regions in LPS-stimulated M1 macrophages. B Venn diagram of 108 overlapping genes from the IRF7 ChIP-seq data and the SCENIC-predicted target genes. C Reactome pathway enrichment of IRF7-regulated genes, highlighting the involvement of NF-κB, TNF, and Toll-like receptor signalling (key genes: IL-1β, FOS, NF-κB1, PTGS2, and CXCL10). D Bulk RNA-seq heatmap showing the upregulation of IRF7 and target genes in M1-polarized macrophages ( GSE130011 , GSE154346 ). E UMAP plots of NFKB1, PTGS2, IL1B, and CXCL10 expression in the CD48 high S100A12 + subcluster. F RT‒qPCR analysis of IRF7 and M1 marker genes in siRNA-treated macrophages (performed in triplicate, with 3 distinct patient sources used for each repetition). G – H Western blot validation of IRF7 and downstream protein expression following IRF7 knockdown in M1-polarized macrophages (performed in triplicate, with 3 distinct patient sources used for each repetition). Statistical significance: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (one-way ANOVA with the Bonferroni post hoc correction)

Article Snippet: Double immunofluorescence staining was performed as follows: sections were incubated overnight at 4 °C with primary antibodies against CD68 (mouse monoclonal, 1:100 dilution; 66231-2-Ig, Proteintech, China) with S100A12 (rabbit polyclonal, 1:100 dilution; 16630-1-AP, Proteintech, China) or CD68 (1:100 dilution; 66231-2-Ig) with IRF7 (rabbit polyclonal, 1:150 dilution; 22392-1-AP, Proteintech, China).

Techniques: ChIP-sequencing, Binding Assay, RNA Sequencing, Expressing, Marker, Western Blot, Biomarker Discovery, Knockdown

Journal: Arthritis Research & Therapy

Article Title: IRF7 orchestrates proinflammatory macrophage polarization and joint destruction in rheumatoid arthritis

doi: 10.1186/s13075-025-03708-3

Figure Lengend Snippet: Local IRF7 knockdown alters the immune cell composition in CIA mice. A Schematic of intra-articular IRF7 siRNA treatment in collagen-induced arthritis (CIA) model mice. B – C Flow cytometry analysis of the CD86 and CD206 mean fluorescence intensities (MFIs) in F4/80 + macrophages from ankle joints ( n = 6). CD86: NC: 1241 ± 265.4, si-IRF7: 2469 ± 390.3, positive: 3489 ± 570.9, si-mock: 3689 ± 370.1. CD206: NC: 2225 ± 225.9, si-IRF7: 3395 ± 369.4, positive: 978.2 ± 147.9, si-mock: 2022 ± 170.6. D – E Frequencies of Foxp3 + Tregs among CD3 + CD4 + T cells ( n = 6). NC: 1.66% ± 0.15%, si-IRF7: 3.27% ± 0.28%, positive: 0.47% ± 0.17%, si-mock: 1.10% ± 0.22%. F Immunofluorescence staining for S100A12 + inflammatory macrophages in the ankle synovium of different groups. Scale bar: 100 μm. The data are presented as the means ± SDs. Statistical significance: *** P < 0.001, **** P < 0.0001 (one-way ANOVA with Bonferroni post hoc correction)

Article Snippet: Double immunofluorescence staining was performed as follows: sections were incubated overnight at 4 °C with primary antibodies against CD68 (mouse monoclonal, 1:100 dilution; 66231-2-Ig, Proteintech, China) with S100A12 (rabbit polyclonal, 1:100 dilution; 16630-1-AP, Proteintech, China) or CD68 (1:100 dilution; 66231-2-Ig) with IRF7 (rabbit polyclonal, 1:150 dilution; 22392-1-AP, Proteintech, China).

Techniques: Knockdown, Flow Cytometry, Fluorescence, Immunofluorescence, Staining

Journal: Arthritis Research & Therapy

Article Title: IRF7 orchestrates proinflammatory macrophage polarization and joint destruction in rheumatoid arthritis

doi: 10.1186/s13075-025-03708-3

Figure Lengend Snippet: Local IRF7 inhibition attenuates joint inflammation and bone erosion in CIA mice. A Representative ankle joint images on day 42 postimmunization. B H&E staining and histological staining. C - E IHC staining for CD68, S100A12, and IRF7 in the ankle synovium. Scale bar: 100 μm. F Quantification of paw thickness at the ankle joint ( n = 6 per group). 42 Days after the first immunization: NC: 8.33 ± 0.02, si-IRF7: 10.39 ± 0.54, positive: 12.08 ± 0.80, si-mock: 12.65 ± 0.57, Statistical significance: **** P < 0.0001 (one-way ANOVA with Bonferroni post hoc correction). G H&E staining and histological scoring of synovial hyperplasia and inflammation ( n = 6). NC: 0.00 (0.00–0.00), si-IRF7: 1.50 (1.00–2.25), positive: 2.50 (1.75–3.00), and si-mock: 3.00 (2.75–3.00). Data are shown as medians with 25% − 75% percentiles. Statistical significance: * P < 0.05 (Kruskal‒Wallis test, followed by post hoc Dunn’s test with Bonferroni correction for multiple comparisons). H - J Semiquantitative analysis analysis of CD68, S100A12, and IRF7 expression via IHC staining via ImageJ ( n = 6). Statistical significance: **** P < 0.0001 (one-way ANOVA with Bonferroni post hoc correction)

Article Snippet: Double immunofluorescence staining was performed as follows: sections were incubated overnight at 4 °C with primary antibodies against CD68 (mouse monoclonal, 1:100 dilution; 66231-2-Ig, Proteintech, China) with S100A12 (rabbit polyclonal, 1:100 dilution; 16630-1-AP, Proteintech, China) or CD68 (1:100 dilution; 66231-2-Ig) with IRF7 (rabbit polyclonal, 1:150 dilution; 22392-1-AP, Proteintech, China).

Techniques: Inhibition, Staining, Immunohistochemistry, Expressing

Journal: Pediatric Research

Article Title: S100A12 on Circulating Endothelial Cells Surface in Children With Kawasaki Disease

doi: 10.1203/pdr.0b013e3181e67ce8

Figure Lengend Snippet: Figure 1. Diagram of CECs/MNC, CECs-S100A12/CECs, and FI- S100A12-CECs measurement by flow cytometry. A, screening MNC (R1); B, screening CECs (R2); C, verifying the CECs again (R3); D, measuring CECs-S100A12/CECs and FI-S100A12-CECs, the green represent the iso- type control scan.

Article Snippet: The samples were divided into two tubes (each with 100 L): one tube was used for testing by adding 10 L polyclonal goat anti-human S100A12 antibody (R&D systems), and the other was used as control by adding goat IgG1.

Techniques: Cytometry, Control

Journal: Pediatric Research

Article Title: S100A12 on Circulating Endothelial Cells Surface in Children With Kawasaki Disease

doi: 10.1203/pdr.0b013e3181e67ce8

Figure Lengend Snippet: Figure 2. Diagram of CECs/MNC, CECs-S100A12/CECs and FI-S100A12-CECs levels in Kawasaki disease with or without coronary artery lesions. A, CECs/MNC levels; B, CECs-S100A12/CECs levels; C, FI-S100A12-CECs levels. CECs/MNC, the ratio of circulating endothelial cells to MNC; CECs-S100A12/CECs, the positive rate of S100A12 on circulating endothelial cells surface; FI-S100A12-CECs, the fluorescence intensity of S100A12 on circulating endothelial cells surface; F, KD without CALs; f, KD with CALs; Œ, Control.

Article Snippet: The samples were divided into two tubes (each with 100 L): one tube was used for testing by adding 10 L polyclonal goat anti-human S100A12 antibody (R&D systems), and the other was used as control by adding goat IgG1.

Techniques: Control

Journal: Journal of Clinical Medicine

Article Title: Circulating Profiles of Serum Proguanylin, S100A12 Protein and Pentraxin 3 as Diagnostic Markers of Ulcerative Colitis

doi: 10.3390/jcm12134339

Figure Lengend Snippet: Characteristics of serum concentrations of proguanylin, S100A12 protein, and pentraxin 3 concentrations in the serum of pre- and post-treatment patients with UC and healthy individuals.

Article Snippet: The measurements of S100A12 concentration in serum was performed using Human S100A12 ELISA test from BioVendor Company (Karasek, Czech Republic).

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Circulating Profiles of Serum Proguanylin, S100A12 Protein and Pentraxin 3 as Diagnostic Markers of Ulcerative Colitis

doi: 10.3390/jcm12134339

Figure Lengend Snippet: Comparison of serum profiles of pro-GN ( A ), S100A12 ( B ) and PTX3 ( C ) in the group of patients with UC before, as well as after, a year of Adalimumab therapy, and in healthy individuals *— p < 0.001; **— p < 0.005; C—healthy individuals; UC0—patients with UC before biological treatment; UC1—patients with UC after a year of treatment.

Article Snippet: The measurements of S100A12 concentration in serum was performed using Human S100A12 ELISA test from BioVendor Company (Karasek, Czech Republic).

Techniques: Comparison

Journal: Journal of Clinical Medicine

Article Title: Circulating Profiles of Serum Proguanylin, S100A12 Protein and Pentraxin 3 as Diagnostic Markers of Ulcerative Colitis

doi: 10.3390/jcm12134339

Figure Lengend Snippet: The significance of correlation between serum profile of analyzed proteins disease activity.

Article Snippet: The measurements of S100A12 concentration in serum was performed using Human S100A12 ELISA test from BioVendor Company (Karasek, Czech Republic).

Techniques: Activity Assay

Journal: Journal of Clinical Medicine

Article Title: Circulating Profiles of Serum Proguanylin, S100A12 Protein and Pentraxin 3 as Diagnostic Markers of Ulcerative Colitis

doi: 10.3390/jcm12134339

Figure Lengend Snippet: Significant relationships between the S100A12, PTX3 concentrations, and disease activity expressed in the Mayo score in patients with UC before and after biological treatment: ( A ) correlation between S100A12 level and disease activity before treatment; ( B ) correlation between PTX3 level and disease activity before treatment; and ( C ) correlation between S100A12 level and disease activity after treatment; blue circles—function from biomarker serum concentration to Mayo score; red line—regression line.

Article Snippet: The measurements of S100A12 concentration in serum was performed using Human S100A12 ELISA test from BioVendor Company (Karasek, Czech Republic).

Techniques: Activity Assay, Biomarker Discovery, Concentration Assay

Journal: iScience

Article Title: Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19.

doi: 10.1016/j.isci.2022.105873

Figure Lengend Snippet: Figure 1. Evaluation of host biomarkers for TB and LTBI in a European cohort Levels of IL-6, IP-10, ferritin, SAA1/A2, CRP, ApoA1, and S100A12 were measured by UCP-LFA in serum samples of TB patients (n = 30; green dots) and LTBI (n = 29; gray dots) from Europe. Median values for each group are indicated by horizontal bars. Mann-Whitney U tests were performed to determine the statistical significance between groups (pvalues: *p%0 $ 05, **p%0 $ 01, ***p%0 $ 001, ****p%0 $ 0001). Green dots: TB cohort 1; gray dots: LTBI cohort 1. AUC: area under the curve; Fc: flow control line; LTBI: latent tuberculosis infection; T: test line; TB: tuberculosis.

Article Snippet: 4 mm width UCP-LF strips specific for a single host protein – ApoA1, CRP, ferritin, IL-6, IP-10, SAA1/A2, and S100A12 - were produced as described earlier.24,28,29 For ApoA1, CRP, ferritin, IL-6, IP-10, SAA1/A2, and S100A12 LF strips, each Test (T) line comprised 200 ng of the following antibodies: goat-anti-human ApoA1 pAb (AF3664; R&D systems, Minneapolis, MN, USA), mouse-anti-human CRP mAb (C5; Labned.com, Amstelveen, the Netherlands), mouse-anti-human ferritin mAb (F31; Novus Biologicals, Littleton, CO, USA), rat-anti-human IL-6 mAb (MQ2-39C3; Biolegend, San Diego, CA, USA), mouse-anti-human IP-10 mAb (B-C55; Diaclone Research, Besancon, France), mouse-anti-human SAA1/A2 mAb (865504; R&D systems, Minneapolis, MN, USA), and goat-anti-human S100A12 pAb (AF1052; R&D systems, Minneapolis, MN, USA), respectively.

Techniques: MANN-WHITNEY, Control, Infection

Journal: iScience

Article Title: Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19.

doi: 10.1016/j.isci.2022.105873

Figure Lengend Snippet: Figure 2. Evaluation of host biomarkers for Dutch COVID-19 patients and healthy controls Levels of IL-6, IP-10, ferritin, SAA1/A2, CRP, ApoA1, and S100A12 were measured by UCP-LFA in serum samples of COVID-19 patients (n = 102) and healthy controls (n = 39; n = 27 from before (May) 2019 (n = 12 from after 2019 (June/July 2020)) from the Netherlands. Median values for each group are indicated by horizontal bars. Mann-Whitney U tests were performed to determine the statistical significance between groups (pvalues: *p%0 $ 05, **p%0 $ 01, ***p%0 $ 001, ****p %0 $ 0001). Orange dots: healthy controls from before 2019; purple dots: healthy controls from after 2019; black dots: COVID-19 patients with a fatal outcome; yellow dots: COVID-19 patients with severe disease; turquoise dots: COVID-19 patients with moderate disease. AUC: area under the curve; COVID-19: coronavirus disease 2019; Fc: flow control line; T: test line.

Article Snippet: 4 mm width UCP-LF strips specific for a single host protein – ApoA1, CRP, ferritin, IL-6, IP-10, SAA1/A2, and S100A12 - were produced as described earlier.24,28,29 For ApoA1, CRP, ferritin, IL-6, IP-10, SAA1/A2, and S100A12 LF strips, each Test (T) line comprised 200 ng of the following antibodies: goat-anti-human ApoA1 pAb (AF3664; R&D systems, Minneapolis, MN, USA), mouse-anti-human CRP mAb (C5; Labned.com, Amstelveen, the Netherlands), mouse-anti-human ferritin mAb (F31; Novus Biologicals, Littleton, CO, USA), rat-anti-human IL-6 mAb (MQ2-39C3; Biolegend, San Diego, CA, USA), mouse-anti-human IP-10 mAb (B-C55; Diaclone Research, Besancon, France), mouse-anti-human SAA1/A2 mAb (865504; R&D systems, Minneapolis, MN, USA), and goat-anti-human S100A12 pAb (AF1052; R&D systems, Minneapolis, MN, USA), respectively.

Techniques: MANN-WHITNEY, Control

Journal: iScience

Article Title: Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19.

doi: 10.1016/j.isci.2022.105873

Figure Lengend Snippet: Figure 3. Evaluation of host biomarkers for TB and COVID-19 patients Levels of IL-6, IP-10, ferritin, SAA1/A2, CRP, ApoA1, and S100A12 were measured by UCP-LFA in serum samples of TB patients (n = 46) and COVID-19 patients (n = 102) collected in European hospitals. Median values for each group are indicated by horizontal bars. Mann-Whitney U tests were performed to determine the statistical significance between groups (pvalues: *p%0 $ 05, **p%0 $ 01, ***p%0 $ 001, ****p%0 $ 0001). Green dots: TB cohort 1; blue dots: TB cohort 2; black dots: COVID-19 patients. AUC: area under the curve; COVID-19: coronavirus disease 2019; Fc: flow control line; T: test line; TB: tuberculosis.

Article Snippet: 4 mm width UCP-LF strips specific for a single host protein – ApoA1, CRP, ferritin, IL-6, IP-10, SAA1/A2, and S100A12 - were produced as described earlier.24,28,29 For ApoA1, CRP, ferritin, IL-6, IP-10, SAA1/A2, and S100A12 LF strips, each Test (T) line comprised 200 ng of the following antibodies: goat-anti-human ApoA1 pAb (AF3664; R&D systems, Minneapolis, MN, USA), mouse-anti-human CRP mAb (C5; Labned.com, Amstelveen, the Netherlands), mouse-anti-human ferritin mAb (F31; Novus Biologicals, Littleton, CO, USA), rat-anti-human IL-6 mAb (MQ2-39C3; Biolegend, San Diego, CA, USA), mouse-anti-human IP-10 mAb (B-C55; Diaclone Research, Besancon, France), mouse-anti-human SAA1/A2 mAb (865504; R&D systems, Minneapolis, MN, USA), and goat-anti-human S100A12 pAb (AF1052; R&D systems, Minneapolis, MN, USA), respectively.

Techniques: MANN-WHITNEY, Control

Journal: iScience

Article Title: Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19.

doi: 10.1016/j.isci.2022.105873

Figure Lengend Snippet: Figure 4. Treatment monitoring for TB Levels of IL-6, IP-10, ferritin, SAA1/A2, CRP, ApoA1, and S100A12 were measured by UCP-LFA in serum samples of pulmonary TB patients (n = 22) before treatment (t0), at months 2–4 (t1), and months 5–9 (t2) of treatment. Median values for each group are indicated by horizontal bars. The gray dotted lines represent the median value of the corresponding marker measured for 39 healthy controls. S100A12 data were missing for one patient. Friedman test with Dunn’s correction for multiple testing was performed to determine the statistical significance between timepoints (pvalues: *p%0 $ 05, **p%0 $ 01, ***p%0 $ 001, ****p%0 $ 0001). Fc: flow control line; T: test line; TB: tuberculosis; t0: first timepoints; t1: 2–4 months after the beginning of treatment; t2: 5–9 months after the beginning of treatment.

Article Snippet: 4 mm width UCP-LF strips specific for a single host protein – ApoA1, CRP, ferritin, IL-6, IP-10, SAA1/A2, and S100A12 - were produced as described earlier.24,28,29 For ApoA1, CRP, ferritin, IL-6, IP-10, SAA1/A2, and S100A12 LF strips, each Test (T) line comprised 200 ng of the following antibodies: goat-anti-human ApoA1 pAb (AF3664; R&D systems, Minneapolis, MN, USA), mouse-anti-human CRP mAb (C5; Labned.com, Amstelveen, the Netherlands), mouse-anti-human ferritin mAb (F31; Novus Biologicals, Littleton, CO, USA), rat-anti-human IL-6 mAb (MQ2-39C3; Biolegend, San Diego, CA, USA), mouse-anti-human IP-10 mAb (B-C55; Diaclone Research, Besancon, France), mouse-anti-human SAA1/A2 mAb (865504; R&D systems, Minneapolis, MN, USA), and goat-anti-human S100A12 pAb (AF1052; R&D systems, Minneapolis, MN, USA), respectively.

Techniques: Marker, Control

Journal: iScience

Article Title: Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19.

doi: 10.1016/j.isci.2022.105873

Figure Lengend Snippet: Figure 5. Treatment monitoring for COVID-19 Levels of IL-6, IP-10, ferritin, SAA1/A2, CRP, ApoA1, and S100A12 were measured by UCP-LFA in serum samples from COVID-19 patients (n = 25) at hospital admission (t0) and follow-up (t2). Median values for each group are indicated by horizontal bars. The gray dotted lines represent the median value of the corresponding marker measured for 39 healthy controls. Wilcoxon matched pairs signed rank tests were performed to determine the statistical significances between timepoints (pvalues: *p%0 $ 05, **p%0 $ 01, ***p%0 $ 001, ****p%0 $ 0001). COVID-19: coronavirus disease 2019; Fc: flow control line; T: test line; t0: timepoint of hospital admission; t2: follow-up around 6 weeks after hospital discharge.

Article Snippet: 4 mm width UCP-LF strips specific for a single host protein – ApoA1, CRP, ferritin, IL-6, IP-10, SAA1/A2, and S100A12 - were produced as described earlier.24,28,29 For ApoA1, CRP, ferritin, IL-6, IP-10, SAA1/A2, and S100A12 LF strips, each Test (T) line comprised 200 ng of the following antibodies: goat-anti-human ApoA1 pAb (AF3664; R&D systems, Minneapolis, MN, USA), mouse-anti-human CRP mAb (C5; Labned.com, Amstelveen, the Netherlands), mouse-anti-human ferritin mAb (F31; Novus Biologicals, Littleton, CO, USA), rat-anti-human IL-6 mAb (MQ2-39C3; Biolegend, San Diego, CA, USA), mouse-anti-human IP-10 mAb (B-C55; Diaclone Research, Besancon, France), mouse-anti-human SAA1/A2 mAb (865504; R&D systems, Minneapolis, MN, USA), and goat-anti-human S100A12 pAb (AF1052; R&D systems, Minneapolis, MN, USA), respectively.

Techniques: Marker, Control

Journal: Viruses

Article Title: High Serum S100A12 as a Diagnostic and Prognostic Biomarker for Severity, Multidrug-Resistant Bacteria Superinfection and Herpes Simplex Virus Reactivation in COVID-19

doi: 10.3390/v16071084

Figure Lengend Snippet: Serum S100A12 levels of healthy controls and patients with COVID-19. ( a ) Serum S100A12 levels of controls, patients with moderate and severe COVID-19; ( b ) receiver operating characteristic curve for discrimination of moderate and severe COVID-19. Outliers are indicated by circles (S100A12 levels >1.5 × the interquartile range) and asterisks (S100A12 levels >3.0 × the interquartile range).

Article Snippet: Serum S100A12 levels were measured using the IDK ® S100A12 ELISA kit (Immundiagnostik AG, Bensheim, Germany).

Techniques:

Journal: Viruses

Article Title: High Serum S100A12 as a Diagnostic and Prognostic Biomarker for Severity, Multidrug-Resistant Bacteria Superinfection and Herpes Simplex Virus Reactivation in COVID-19

doi: 10.3390/v16071084

Figure Lengend Snippet: Serum S100A12 levels (µg/mL) of patients on dialysis and vasopressor therapy in comparison to patients without this intervention/therapy.

Article Snippet: Serum S100A12 levels were measured using the IDK ® S100A12 ELISA kit (Immundiagnostik AG, Bensheim, Germany).

Techniques: Comparison

Journal: Viruses

Article Title: High Serum S100A12 as a Diagnostic and Prognostic Biomarker for Severity, Multidrug-Resistant Bacteria Superinfection and Herpes Simplex Virus Reactivation in COVID-19

doi: 10.3390/v16071084

Figure Lengend Snippet: Spearman correlation coefficients for the correlation of serum S100A12 levels with inflammatory parameters and immune cell counts.

Article Snippet: Serum S100A12 levels were measured using the IDK ® S100A12 ELISA kit (Immundiagnostik AG, Bensheim, Germany).

Techniques: Marker

Journal: Viruses

Article Title: High Serum S100A12 as a Diagnostic and Prognostic Biomarker for Severity, Multidrug-Resistant Bacteria Superinfection and Herpes Simplex Virus Reactivation in COVID-19

doi: 10.3390/v16071084

Figure Lengend Snippet: Serum S100A12 levels of patients with severe COVID-19 and bacterial superinfection or herpes simplex virus reactivation. ( a ) Serum S100A12 levels of patients with severe COVID-19 without (No) and with (Yes) bacteremia; ( b ) serum S100A12 levels of patients with severe COVID-19 without (No) and with (Yes) vancomycin-resistant bacteria (VRE) superinfection ( c ) ROC curve for the discrimination of patients with and without vancomycin-resistant bacteria; ( d ) serum S100A12 levels of patients with severe COVID-19 with (Yes) and without (No) herpes simplex virus (HSV) reactivation. Outliers are indicated by circles (S100A12 levels >1.5 × the interquartile range) and asterisks (S100A12 levels >3.0 × the interquartile range).

Article Snippet: Serum S100A12 levels were measured using the IDK ® S100A12 ELISA kit (Immundiagnostik AG, Bensheim, Germany).

Techniques: Virus, Bacteria

Journal: Viruses

Article Title: High Serum S100A12 as a Diagnostic and Prognostic Biomarker for Severity, Multidrug-Resistant Bacteria Superinfection and Herpes Simplex Virus Reactivation in COVID-19

doi: 10.3390/v16071084

Figure Lengend Snippet: Serum S100A12 and survival. Serum S100A12 levels of surviving and non-surviving patients with severe COVID-19. Outliers are indicated by circles (S100A12 levels >1.5 × the interquartile range) and asterisks (S100A12 levels >3.0 × the interquartile range).

Article Snippet: Serum S100A12 levels were measured using the IDK ® S100A12 ELISA kit (Immundiagnostik AG, Bensheim, Germany).

Techniques: